Anti-ICAM-1 monoclonal antibody 1A-29

Drug Profile

Anti-ICAM-1 monoclonal antibody 1A-29

Alternative Names: 1A-29; Monoclonal antibody 1A-29

Latest Information Update: 01 Aug 2002

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Johns Hopkins University; Nonindustrial source; Pharmacia Corporation
  • Developer Nonindustrial source
  • Class Anti-ischaemics; Monoclonal antibodies
  • Mechanism of Action Intercellular adhesion molecule 1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Multiple sclerosis; Transplant rejection

Most Recent Events

  • 05 Apr 2000 Pharmacia & Upjohn merged with Monsanto to form Pharmacia Corporation
  • 12 Oct 1998 A preclinical study has been added to the pharmacodynamics section
  • 05 Oct 1998 No-Development-Reported for Multiple sclerosis (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top